EN | UA
EN | UA

Help Support

Back

Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk

Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk
Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk

To estimate the fracture risk among postmenopausal females with osteoporosis following discontinuing BP treatment.

See All

Key take away

Biophosphates (BP) are the first line drug used to reduce the risk of vertebral, hip, and non-vertebral fractures in postmenopausal women with osteoporosis. For most postmenopausal womens with osteoporosis the benifit of BP outweight the risks. Therefore this study reported the 40% incresed of clinical fractures in womens who took a BP drug holiday.

Background

To estimate the fracture risk among postmenopausal females with osteoporosis following discontinuing BP treatment.

Method

A total of 108 postmenopausal females with osteoporosis who had undergone a “drug holiday” or continued therapy following first-line BP therapy were selected for analysis. The appearance of new clinical fractures at the time of follow-up was also investigated. The associations between BP “drug holiday” and the appearance of clinical fractures while checking for confounding factors were identified applying the Cox proportional hazards models. Log-rank tests and Kaplan-Meier curves were used to analyse the survival without new clinical fractures.

Result

The patients obtained  Risedronate, Ibandronate, Alendronate, and Zoledronic acid. One hundred sixty-six patients showed 6 to 36 months of follow-up. The rates of new clinical fractures at follow-up were 16.1% for “drug holiday” group and 11.9%for another group. After full adjustment, the “drug holiday” patients showed 1.40 hazard ratio of new clinical fractures. 

Conclusion

The risk of recently found clinical fractures was 40% greater among patients who received a Bisphosphonate drug holiday after the first-line BP therapy. 

Source:

Osteoporosis International

Article:

Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk

Authors:

M. A. Mignot et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: